- Collaboration leverages Ascendis’ proprietary TransCon™ technologies and Novo Nordisk’s expertise in cardiometabolic diseases
- Once-monthly GLP-1 receptor agonist will be the collaboration’s lead product candidate
https://www.globenewswire.com/news-release/2024/11/04/2973903/0/en/Ascendis-Pharma-and-Novo-Nordisk-Sign-Collaboration-for-Development-and-Commercialization-of-TransCon-Technology-based-Products-in-Metabolic-and-Cardiovascular-Diseases.html
Note: Only a member of this blog may post a comment.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.